MatchMedi
English

선택지 정리됨

Ovarian cancer: 국가별 선택지

이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.

선택지 정리됨고형암최종 확인 2026.06

현재 제공

국가별 선택지를 정리합니다

국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.

아직 하지 않음

치료 선택을 지시하지 않습니다

이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.

출처

공신력 있는 출처 기반

모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.

진료 전 정리할 정보

  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.

임상시험 검색어

Ovarian cancer clinical trial

국가별 선택지

국가별 치료 선택지

공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.

United States

  • Bevacizumab (Avastin) + carboplatin + paclitaxel, followed by single-agent bevacizumab[1]FDA-approvedno biomarker selector stated in the fetched FDA sources; stage III or IV disease following initial surgical resection; front-line chemotherapy followed by bevacizumab maintenance continuation. · This finding is specific to stage III or IV disease after initial surgical resection and should not be generalized to every ovarian setting. The FDA-hosted label file is an older label artifact and should be refreshed before patient-facing reuse. Confidence/conflicts: High for the stage III-IV post-surgical approval wording; current-label refresh remains advisable because the fetched PDF is an older label artifact.
  • Bevacizumab (Avastin) + carboplatin + paclitaxel, followed by single-agent bevacizumab[1]FDA-approvedno biomarker selector stated in the fetched FDA sources; stage III or IV disease following initial surgical resection; front-line chemotherapy followed by bevacizumab maintenance continuation. · This finding is specific to stage III or IV disease after initial surgical resection and should not be generalized to every ovarian setting. The FDA-hosted label file is an older label artifact and should be refreshed before patient-facing reuse. Confidence/conflicts: High for the stage III-IV post-surgical approval wording; current-label refresh remains advisable because the fetched PDF is an older label artifact.
  • Niraparib (Zejula)[2]FDA-approvedno FDA-approved companion diagnostic required for this first-line maintenance indication; first-line maintenance after complete or partial response to platinum-based chemotherapy. · This finding verifies the broad U.S. first-line maintenance indication, not relative benefit across biomarker subgroups, later-line withdrawn uses, or payer coverage. Weight- and platelet-based dosing details exist in the source but are not a MatchMedi eligibility shortcut. Confidence/conflicts: High for the FDA first-line maintenance indication and no-companion-diagnostic statement; no conflict identified.
  • Olaparib (Lynparza)[3]FDA-approveddeleterious or suspected deleterious germline or somatic BRCA mutation required; first-line maintenance after complete or partial response to platinum-based chemotherapy. · The fetched FDA-hosted label PDF is a 2020 label file and carries the standard note that it may not be the latest approved label; use it as a verified indication source, but refresh before patient-facing reuse. This finding does not establish payer coverage or individual companion-diagnostic availability. Confidence/conflicts: Moderate-high for the FDA-hosted indication text; current-label refresh remains advisable because the fetched PDF is not the newest label artifact.
  • Olaparib (Lynparza) + bevacizumab[3]FDA-approvedhomologous recombination deficiency (HRD) positive status required, defined by deleterious or suspected deleterious BRCA mutation and/or genomic instability; FDA-approved companion diagnostic referenced; first-line maintenance after complete or partial response to platinum-based chemotherapy. · This is an HRD-selected maintenance indication, not a general all-comers ovarian maintenance claim. The FDA notice and label do not establish payer coverage or local testing logistics. Confidence/conflicts: High for the approval notice and consistent FDA-hosted label wording; no source conflict identified.
  • mirvetuximab soravtansine-gynx (Elahere)[4]FDA-approvedfolate receptor alpha (FR-alpha) positive by FDA-approved test; platinum-resistant disease after one to three prior systemic treatment regimens. · Requires FR-alpha-positive testing with an FDA-approved test and applies to the specified platinum-resistant/prior-treatment setting. It is not a general ovarian cancer option for all patients. Confidence/conflicts: high for FDA approval notice; no conflict identified.
  • olaparib (Lynparza), including monotherapy maintenance and olaparib plus bevacizumab maintenance indications[5]FDA-approveddeleterious or suspected deleterious germline or somatic BRCA mutation for olaparib monotherapy; HRD-positive status for olaparib plus bevacizumab context per FDA label; first-line maintenance after complete or partial response to first-line platinum-based chemotherapy; bevacizumab combination in HRD-positive disease after platinum-based chemotherapy plus bevacizumab. · Biomarker testing and exact maintenance setting are essential. FDA PARP inhibitor indications have changed over time, so current label should be used rather than older ovarian PARP summaries. Confidence/conflicts: high for current FDA label; no conflict identified.
  • platinum-based chemotherapy approaches as described by NCI PDQ, including chemotherapy in early-stage selected settings, advanced-stage treatment, and recurrent/persistent disease contexts[6]Standard option (per NCI PDQ)not biomarker-specific; early-stage selected settings, advanced-stage disease, recurrent or persistent disease. · Regimen choice and sequencing depend on stage, prior treatment, platinum sensitivity, histology, toxicity, and patient goals. No dosing or regimen ranking is provided here. Confidence/conflicts: high for NCI PDQ treatment-category support; no conflict identified.
  • recurrent/persistent disease management options including systemic therapy, surgery in selected contexts, and symptom-directed supportive care as described by NCI PDQ[6]Standard option (per NCI PDQ)depends on recurrence treatment; not biomarker-specific for supportive/palliative local management; recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer. · Supportive care and recurrent-disease treatment depend on symptoms, prior therapies, platinum interval, disease sites, and patient goals. This entry does not imply any specific intervention is appropriate. Confidence/conflicts: high for NCI PDQ recurrent/supportive context; no conflict identified.
  • surgical staging and cytoreductive surgery / debulking surgery[6]Standard option (per NCI PDQ)not biomarker-specific; early-stage and advanced-stage treatment contexts as described by NCI PDQ. · Surgical approach depends on stage, resectability, histology, fitness, fertility goals where relevant, and gynecologic-oncology expertise. This is an option to discuss with the treating team. Confidence/conflicts: high for NCI PDQ treatment-category support; no conflict identified.

European Union

  • mirvetuximab soravtansine (Elahere)[7]EMA authorisedfolate receptor-alpha positive; advanced FR-alpha-positive disease resistant to platinum-based treatment. · EMA central authorisation does not establish reimbursement or local availability in every EU member state. FR-alpha testing and exact prior-treatment criteria require local label/pathway confirmation. Confidence/conflicts: high for EMA authorised indication; no conflict identified.
  • niraparib (Zejula)[8]EMA authorisedno biomarker restriction stated for the broad EMA first-line maintenance indication in fetched EPAR overview; biomarker status may affect national reimbursement; maintenance after complete or partial response to platinum-based chemotherapy in advanced or relapsed platinum-sensitive settings. · EMA authorisation does not determine member-state reimbursement. Current national restrictions may narrow by biomarker or setting; confirm local criteria before surfacing. Confidence/conflicts: medium-high; EMA indication support is clear, but national restrictions may be narrower. No conflict identified.
  • olaparib (Lynparza) monotherapy or olaparib with bevacizumab[9]EMA authorisedBRCA mutation and HRD-positive contexts per EMA product information; maintenance after response to platinum-based chemotherapy; first-line advanced high-grade maintenance contexts. · Biomarker requirements and bevacizumab exposure differ by maintenance pathway. EMA authorisation does not determine national reimbursement. Confidence/conflicts: high for EMA authorised indication; no conflict identified.

United Kingdom

  • mirvetuximab soravtansine (Elahere)[10]ApprovedFR-alpha positive; FR-alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer within marketing-authorisation scope. · Because the fetched NICE appraisal page is still in development, treat this as a high-priority follow-up cell. Verify final NICE guidance after 2026-06-17 before integrating as a stable NHS option. Confidence/conflicts: medium; news reports approval, while the fetched NICE appraisal page remains in development with a future publication date. Flag final NICE publication follow-up.
  • niraparib (Zejula)[11]NICE recommendednot restricted in the NICE CG122 summary; TA1129 criteria include first-line bevacizumab non-use or intolerance; maintenance after response to first-line platinum-based chemotherapy; if first-line bevacizumab was not used or not tolerated. · NICE recommendation is restricted by bevacizumab exposure/tolerance and commercial arrangement in TA1129. Confirm the current appraisal details and local NHS criteria. Confidence/conflicts: high for NICE/NCBI recommendation text; no conflict identified.
  • olaparib (Lynparza)[11]NICE recommendedBRCA mutation-positive; maintenance after response to first-line platinum-based chemotherapy. · NICE England recommendation applies to the specified stage, histology, biomarker, and response setting. Devolved/private access may differ. Confidence/conflicts: high for NICE recommendation; no conflict identified.
  • olaparib (Lynparza) with bevacizumab[11]NICE recommendedhomologous recombination deficiency positive; maintenance after complete or partial response to first-line platinum-based chemotherapy with bevacizumab. · Requires HRD-positive status and prior bevacizumab with first-line platinum-based chemotherapy. NICE notes a commercial access arrangement for olaparib in TA946. Confidence/conflicts: high for NICE recommendation; no conflict identified.

Japan

  • cytoreductive surgery followed by platinum-based chemotherapy, most commonly paclitaxel plus carboplatin, with bevacizumab addition/maintenance in selected contexts[12]Standard option (per Drugs - Real World Outcomes / Springer)not biomarker-specific for surgery/chemotherapy backbone; advanced epithelial ovarian cancer initial treatment backbone. · This is a peer-reviewed summary of Japanese guideline practice, not the guideline text itself. Confirm the current Japanese guideline, surgical candidacy, and bevacizumab eligibility locally. Confidence/conflicts: medium-high; source summarizes guideline practice but primary guideline text remains a follow-up gap. No conflict identified.
  • niraparib (Zejula)[13]PMDA-approved (Japan)not restricted in the PMDA review-report indication text excerpt for initial-chemotherapy maintenance; precise biomarker criteria should be confirmed in current label; maintenance after response to platinum-based chemotherapy in platinum-sensitive relapsed high-grade serous disease; maintenance after initial chemotherapy with stage III/IV precautions. · PMDA review report should be paired with the current Japanese package insert for exact biomarker/stage wording and insurance criteria. Confidence/conflicts: high for PMDA review-report content; current-label refresh remains a gap. No conflict identified. Availability/reimbursement outside the approving regulator not established.
  • platinum-based chemotherapy or chemotherapy plus bevacizumab, followed by PARP inhibitor or bevacizumab maintenance in selected platinum-sensitive recurrent ovarian cancer contexts[14]Standard option (per Journal of Gynecologic Oncology)BRCA/HRD status discussed for PARP decisions; not required in all cited East Asian practice summaries; platinum-sensitive recurrent ovarian cancer. · This is a regional East Asian strategy review, not a Japan regulator label. Reuse of PARP inhibitors after prior PARP exposure is specifically discouraged in the fetched review. Confidence/conflicts: medium-high; regional review supports strategy but Japan-specific label/reimbursement should be checked. No conflict identified.

Russia

  • Molecular testing to guide PARP inhibitor, anti-HER2, and immunotherapy discussions[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)BRCA1/2 pathogenic mutations, HRD status, HER2/neu in recurrent disease, MMR deficiency in selected recurrent endometrioid/mucinous/clear-cell disease; Diagnostic and recurrent-disease biomarker testing contexts. · Testing availability, validated assays, reimbursement, and treatment access are not established by the guideline alone. Confidence/conflicts: Medium-high for testing recommendations; treatment registration/reimbursement for each biomarker-directed therapy remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Molecular testing to guide PARP inhibitor, anti-HER2, and immunotherapy discussions[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)BRCA1/2 pathogenic mutations, HRD status, HER2/neu in recurrent disease, MMR deficiency in selected recurrent endometrioid/mucinous/clear-cell disease; Diagnostic and recurrent-disease biomarker testing contexts. · Testing availability, validated assays, reimbursement, and treatment access are not established by the guideline alone. Confidence/conflicts: Medium-high for testing recommendations; treatment registration/reimbursement for each biomarker-directed therapy remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Molecular testing to guide PARP inhibitor, anti-HER2, and immunotherapy discussions[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)BRCA1/2 pathogenic mutations, HRD status, HER2/neu in recurrent disease, MMR deficiency in selected recurrent endometrioid/mucinous/clear-cell disease; Diagnostic and recurrent-disease biomarker testing contexts. · Testing availability, validated assays, reimbursement, and treatment access are not established by the guideline alone. Confidence/conflicts: Medium-high for testing recommendations; treatment registration/reimbursement for each biomarker-directed therapy remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • PARP-inhibitor maintenance such as olaparib or niraparib, with or without bevacizumab depending on prior therapy and biomarker context[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)BRCA1/2 and HRD status are relevant for PARP maintenance selection in source; Maintenance after first-line platinum response in advanced ovarian/fallopian/primary peritoneal cancer. · This finding is guideline-level; direct Russian labels, reimbursement, procurement, HRD-test access, and brand-specific restrictions for olaparib/niraparib/bevacizumab were not verified in this batch. Confidence/conflicts: Medium for treatment-access specifics because guideline was fetched but direct Russian labels were not; high for biomarker-guided maintenance concept in the guideline. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Platinum-containing chemotherapy, commonly taxane/platinum backbone; neoadjuvant chemotherapy when upfront surgery or biopsy-only strategy is used[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)Not biomarker-selected; Adjuvant, neoadjuvant, and therapeutic chemotherapy contexts. · Timing, regimen choice, and number of cycles depend on stage, histology, surgical staging completeness, performance status, residual disease, and response. This is guideline evidence, not reimbursement or brand availability. Confidence/conflicts: Medium-high for guideline role; individual regimen details not inferred. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Primary cytoreductive surgery, surgical staging, omentectomy, lymph-node assessment when indicated, and selected fertility-sparing surgery[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)Not biomarker-selected; Primary treatment and staging for epithelial ovarian, primary peritoneal, and fallopian tube cancer. · Surgical choices depend on stage, histology, residual-disease feasibility, fertility goals, hereditary-risk status, and specialist gynecologic-oncology review. Russian-language clinical content requires human review. Confidence/conflicts: Medium-high for guideline content; local center capability and individual eligibility not inferred. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Recurrent-disease systemic therapy selected by platinum sensitivity, prior therapy, and biomarker findings; supportive symptom-directed care when disease control is not feasible[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)Platinum sensitivity, BRCA/HRD status, HER2/neu, and MMR deficiency may affect options in source; Recurrent ovarian/fallopian/primary peritoneal cancer. · Product-specific approvals, reimbursement, clinical-trial access, and individual eligibility are not established. Recurrent disease treatment can be strongly affected by prior PARP/bevacizumab exposure and cumulative toxicity. Confidence/conflicts: Medium-high for guideline framework; individual drug access remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Recurrent-disease systemic therapy selected by platinum sensitivity, prior therapy, and biomarker findings; supportive symptom-directed care when disease control is not feasible[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)Platinum sensitivity, BRCA/HRD status, HER2/neu, and MMR deficiency may affect options in source; Recurrent ovarian/fallopian/primary peritoneal cancer. · Product-specific approvals, reimbursement, clinical-trial access, and individual eligibility are not established. Recurrent disease treatment can be strongly affected by prior PARP/bevacizumab exposure and cumulative toxicity. Confidence/conflicts: Medium-high for guideline framework; individual drug access remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Recurrent-disease systemic therapy selected by platinum sensitivity, prior therapy, and biomarker findings; supportive symptom-directed care when disease control is not feasible[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)Platinum sensitivity, BRCA/HRD status, HER2/neu, and MMR deficiency may affect options in source; Recurrent ovarian/fallopian/primary peritoneal cancer. · Product-specific approvals, reimbursement, clinical-trial access, and individual eligibility are not established. Recurrent disease treatment can be strongly affected by prior PARP/bevacizumab exposure and cumulative toxicity. Confidence/conflicts: Medium-high for guideline framework; individual drug access remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.
  • Recurrent-disease systemic therapy selected by platinum sensitivity, prior therapy, and biomarker findings; supportive symptom-directed care when disease control is not feasible[15]Standard option (per Russian Society of Clinical Oncology / RosOncoWeb)Platinum sensitivity, BRCA/HRD status, HER2/neu, and MMR deficiency may affect options in source; Recurrent ovarian/fallopian/primary peritoneal cancer. · Product-specific approvals, reimbursement, clinical-trial access, and individual eligibility are not established. Recurrent disease treatment can be strongly affected by prior PARP/bevacizumab exposure and cumulative toxicity. Confidence/conflicts: Medium-high for guideline framework; individual drug access remains source-pending. Primary source is in Russian. English summary pending human review — confirm exact wording with your care team.

Thailand

출처

  1. U.S. Food and Drug Administration (FDA) — official drug label · official drug label
  2. U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
  3. U.S. Food and Drug Administration (FDA) — official drug label · official drug label
  4. U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
  5. U.S. Food and Drug Administration (FDA) — drug label / prescribing information · drug label / prescribing information
  6. National Cancer Institute (NCI) — national cancer agency evidence summary · national cancer agency evidence summary
  7. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  8. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  9. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  10. National Institute for Health and Care Excellence (NICE) — technology appraisal in development · technology appraisal in development
  11. National Institute for Health and Care Excellence (NICE) — national guideline with technology-appraisal cross-references · national guideline with technology-appraisal cross-references
  12. Drugs - Real World Outcomes / Springer — peer-reviewed Japanese real-world cohort with guideline-practice summary · peer-reviewed Japanese real-world cohort with guideline-practice summary
  13. Pharmaceuticals and Medical Devices Agency (PMDA) — regulator review report · regulator review report
  14. Journal of Gynecologic Oncology — peer-reviewed East Asian treatment-strategy review · peer-reviewed East Asian treatment-strategy review
  15. Russian Society of Clinical Oncology (RUSSCO) / RosOncoWeb — professional society clinical recommendations PDF · professional society clinical recommendations PDF
  16. Thai National Drug Information / Thai FDA-MOPH — prescribing information PDF / regulator drug-information repository · prescribing information PDF / regulator drug-information repository
  17. Thai National Drug Information / Thai FDA-MOPH — prescribing information PDF / regulator drug-information repository · prescribing information PDF / regulator drug-information repository

위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.